Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT001 in Recurrent Glioblastoma Harbouring STAT3-High Signature
NCT06894225Phase 2Recruiting
- Sponsor
- National Neuroscience Institute
- Start
- Mar 2025
- Primary completion
- May 2027
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dimethylaminomicheliolide in glioblastoma (GBM), sponsored by National Neuroscience Institute. Started Mar 2025; status: recruiting.
02
Drugs
dimethylaminomicheliolide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06894225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06894225.